Broad Range of Partnered and Proprietary Products



PRODUCT, COLLABORATION PRODUCTS
AND PRODUCT CANDIDATES
THERAPEUTIC
AREA
RESEARCH
FOCUS
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Filed
  • Approved

ONCOLOGY PIPELINE & PRODUCT CANDIDATES

 
 
 
 
 
 
PEGPH20 with ABRAXANE® (nab-paclitaxel)
and gemcitabine*
Oncology
Pancreatic Cancer
 
 
 
 
 
 
PEGPH20 with KEYTRUDA® (pembrolizumab)
Oncology
Gastric/Non-Small Cell Lung Cancer
 
 
 
 
 
 
PEGPH20 with HALAVEN® (eribulin)
Oncology
Breast Cancer (Eisai)
 
 
 
 
 
 
PEGPH20 with TECENTRIQ® (atezolizumab)
Oncology
Pancreas/Gastric (Genentech)
Scheduled to begin 2H 2017
 
 
 
 
 
 
PEGPH20 with TECENTRIQ® (atezolizumab)
Oncology
Gall bladder & cholangiocarcinoma
Scheduled to begin 2H 2017
 
 
 
 
 
 
HTI-1511: anti-EGFR Antibody-Drug
Conjugate (ADC)
Oncology
Various
 
 
 
 
 
 
PEG-ADA2: PEGylated-Human Adenosine
Deaminase 2
Oncology
Various
 
 
 
 
 
 
PRODUCT, COLLABORATION PRODUCTS
AND PRODUCT CANDIDATES
THERAPEUTIC
AREA
APPROVED
INDICATION
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Filed
  • Approved

PROPRIETARY APPROVED PRODUCT

 
 
 
 
 
 
HYLENEX® recombinant
(hyaluronidase human injection)
Various
Adjuvant for Sub-Q fluid delivery for dispersion and absorption of other injected drugs
U.S. Approved
 
 
 
 
 
 

ENHANZE™ COLLABORATION APPROVED PRODUCTS

Roche

 
 
 
 
 
 
Herceptin® SC (trastuzumab)
Oncology
Breast Cancer
Approved in EU and other countries outside the U.S.
 
 
 
 
 
 
MabThera® SC (rituximab)
Oncology
MabThera® SC (rituximab)
Chronic Lymphocytic Leukemia
Approved in EU and other countries outside the U.S. Approved for CLL in EU only. U.S. filing has been accepted.
 
 
 
 
 
 

Baxalta

 
 
 
 
 
 
HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
Immunology
Primary Immunodeficiency
Approved in EU, US, Puerto Rico and Australia
 
 
 
 
 
 
PRODUCT, COLLABORATION PRODUCTS
AND PRODUCT CANDIDATES
THERAPEUTIC
AREA
RESEARCH
FOCUS
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Filed
  • Approved

ENHANZE™ COLLABORATION PRODUCT CANDIDATES

Roche (Total of 8 potential targets)

 
 
 
 
 
 
PERJETA® (pertuzumab)
Oncology
Breast Cancer
 
 
 
 
 
 
Pfizer (Total of 6 potential targets)
Undisclosed
 
 
 
 
 
 

Janssen (Total of 5 potential targets)

 
 
 
 
 
 
daratumumab (DARZALEX®)
Oncology
Multiple Myeloma
 
 
 
 
 
 
AbbVie (Total of 9 potential targets)
Undisclosed
 
 
 
 
 
 
Lilly (Total of 5 potential targets)
Undisclosed
 
 
 
 
 
 

All trademarks belong to their respective owners.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok